CAR T Cells Show Promise in Relapsed/Refractory Hodgkin Lymphoma, ALCL – OncLive
OncLive |
CAR T Cells Show Promise in Relapsed/Refractory Hodgkin Lymphoma, ALCL
OncLive In phase I results published in the Journal of Clinical Investigation, researchers have determined that CD30-specific chimeric antigen receptor (CAR) T cells could be used safely and induce durable complete responses in patients with Hodgkin lymphoma … |
